Seaside Ventures
VC Fund
Austin, United States
Seaside Ventures is a VC fund in Austin focused on Health Care and Biotechnology. We are redefining quality of life by investing in science-driven consumer health technologies. Positioned within the $4.5 trillion healthcare market, we tackle root causes of health challenges, paving the way for a future of proactive, preventative care.Our Mission? To elevate the mental and physical well-being of over a billion people globallyby turning transformative innovation into accessible solutions that improve lives at scale.
- Total investments:
- 45
- Last investment:
- Lead investor:
- 2%
Last updated:
For AI agents: llms.txt
Industries Seaside Ventures invests in
Stages Seaside Ventures invests in
Countries Seaside Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Harrison Valner
|
|||
Ryan Roddy
|
|||
Investment Focus
Industry
- Health Care 9 (20%)
- Biotechnology 6 (13%)
- Food and Beverage 4 (9%)
- Medical 3 (7%)
- Wellness 3 (7%)
Stage
- Seed 13 (29%)
- Series A 6 (13%)
- Pre-Seed 4 (9%)
- Funding Round 1 (2%)
Country
- United States 19 (42%)
- United Kingdom 2 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Harrison Valner
Managing Partner and Founder
|
Managing Partner and Founder | Total investments: 17 | Find email | |
|
Ryan Roddy
Managing Partner and Founder
|
Managing Partner and Founder | Total investments: 20 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Adaptyx Biosciences
|
Adaptyx Biosciences develops wearable sensors. | $14M / Seed / Oct 20, 2025 | |
Ketone-IQ
|
Ketone-IQ offers subscription-based cognitive supplements designed to enhance mental performance and overall brain health. | Series A / Aug 26, 2025 | |
BiomeSense
|
BiomeSense is developing the first technology platform for continuous, at-home monitoring of the human gut microbiome, transforming the ability to understand & utilize the microbiome for precision medicine. The enabling technology is the GutLab, the first “smart bathroom” system for at-home microbiome monitoring, which is combined with theMetaBiome time-series analytics platform into a single end-to-end solution. The platform allows scientists, patients, and consumers the unprecedented ability to tie microbiome changes directly to clinical outcomes in real time, revolutionizing the ability to leverage the microbiome for better health. | Seed / Aug 12, 2025 | |
Circulate
|
Circulate is developing science-based therapeutics that expand your quality of life and healthy lifespan. | $12M / Seed / Jun 30, 2025 | |
StimScience
|
StimScience is focused on commercializing our breakthrough neuroscience and sleep research into life-changing products and services for individuals, employers, and health plans.Our team has spent decades pioneering sleep research and non-invasive, personalized brain stimulation applications. It includes world-renowned scientists and advisors Dr.Matthew Walker, Ph.D., Dr. Rich Ivry, Ph.D., Dr. Robert Knight, M.D., Dr. Ram Gurumoorthy, and former Fitbit, Google, and Samsung employees.With initial funding from Khosla Ventures, we are building a world-class team to launch Somnee, our advanced diagnostic and therapeutic products that help people fall asleep faster and with longer, higher-quality restorative sleep.Why Sleep? As our founding Chief Science Advisor, Dr Matthew Walker wrote in his bestselling book, "Why We Sleep", “Sleep is the most important thing we can do to reset our brain and body health each day.” Sleep health is central to mental health, long-term memory, learning, and physical fitness. Despite its importance, one in three adults gets an unhealthy amount of sleep, and 51% of people are dissatisfied with their sleep.Sleep is one of the most critical functions of the brain, and our deep understanding of the neuroscience of sleep uniquely positions us to help solve the sleep health epidemic. | $10M / Seed / Jun 10, 2025 | |
Rorra
|
Rorra creates plumbing-free water filtration products to provide safe drinking water for individuals. | Seed / Jun 04, 2025 | |
Samphire Neuroscience
|
Samphire Neuroscience builds clinically validated neurotechnology to support women across their lives. Our wearable devices, Nettle™ and Lutea™, are built on the same underlying brain-stimulation technology, targeting neural pathways involved in pain, mood, stress, and sleep regulation. - Lutea™ is available globally as a wellness device. Itstimulates the same regions of the brain to support stress regulation, sleep, and recovery - key drivers of readiness and long-term performance - allowing athletes and teams to move beyond wellbeing education alone to practical, evidence-based intervention. - Nettle™ is a CE-marked (EU and UK regulated), drug- and hormone-free device that has been clinically shown to improve pain, mood, functionality, and the ability to train during the menstrual cycle, with measurable benefits after one month of use - supporting athletes to maintain training intensity and movement quality during their period. - The Samphire App is the platform controlling all Samphire hardware products with the use of CycleSync™ AI technology: the only one of its kind to support personalized neurotechnology use for women. | $5M / Seed / Jun 03, 2025 | |
|
Samphire Neuroscience
|
Samphire Neuroscience builds clinically validated neurotechnology to support women across their lives. Our wearable devices, Nettle™ and Lutea™, are built on the same underlying brain-stimulation technology, targeting neural pathways involved in pain, mood, stress, and sleep regulation. - Lutea™ is available globally as a wellness device. Itstimulates the same regions of the brain to support stress regulation, sleep, and recovery - key drivers of readiness and long-term performance - allowing athletes and teams to move beyond wellbeing education alone to practical, evidence-based intervention. - Nettle™ is a CE-marked (EU and UK regulated), drug- and hormone-free device that has been clinically shown to improve pain, mood, functionality, and the ability to train during the menstrual cycle, with measurable benefits after one month of use - supporting athletes to maintain training intensity and movement quality during their period. - The Samphire App is the platform controlling all Samphire hardware products with the use of CycleSync™ AI technology: the only one of its kind to support personalized neurotechnology use for women. | $5M / Seed / Jun 03, 2025 | |
|
Adaptyx Biosciences
|
Adaptyx Biosciences develops wearable sensors. | Seed / Dec 06, 2024 | |
Paterna Biosciences
|
Paterna Biosciences is an early-stage biotechnology startup that focuses on male reproductive health at the cellular level. The company aims to engage men in optimizing their reproductive and offspring health and establish a balanced fertility market, enabling clinics to solve both male and female challenges. | $6.4M / Seed / Oct 28, 2024 | |
| See all 45 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Seaside Ventures invest in?
Seaside Ventures invests primarily in Health Care, Biotechnology and Food and Beverage startups, most often at Seed and Series A stage. Most of the 45 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Seaside Ventures?
Public channels for Seaside Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Seaside Ventures?
The team at Seaside Ventures includes Harrison Valner (Managing Partner and Founder) and Ryan Roddy (Managing Partner and Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
